Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Altimmune (ALT) Change in Accured Expenses: 2010-2025

Historic Change in Accured Expenses for Altimmune (ALT) over the last 15 years, with Sep 2025 value amounting to $102,000.

  • Altimmune's Change in Accured Expenses rose 102.15% to $102,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $408,000, marking a year-over-year increase of 138.53%. This contributed to the annual value of -$112,000 for FY2024, which is 94.05% up from last year.
  • Altimmune's Change in Accured Expenses amounted to $102,000 in Q3 2025, which was up 127.95% from -$365,000 recorded in Q2 2025.
  • Altimmune's Change in Accured Expenses' 5-year high stood at $11.0 million during Q3 2021, with a 5-year trough of -$9.2 million in Q4 2021.
  • For the 3-year period, Altimmune's Change in Accured Expenses averaged around -$359,727, with its median value being -$365,000 (2025).
  • Per our database at Business Quant, Altimmune's Change in Accured Expenses spiked by 835.00% in 2021 and then crashed by 392.00% in 2024.
  • Quarterly analysis of 5 years shows Altimmune's Change in Accured Expenses stood at -$9.2 million in 2021, then skyrocketed by 76.54% to -$2.2 million in 2022, then skyrocketed by 165.82% to $1.4 million in 2023, then spiked by 66.55% to $2.4 million in 2024, then soared by 102.15% to $102,000 in 2025.
  • Its last three reported values are $102,000 in Q3 2025, -$365,000 for Q2 2025, and -$1.7 million during Q1 2025.